Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Necroptosis is a form of regulated cell death that has been implicated in multiple diseases. TNF-induced necroptosis is regulated by necrosomes, complexes consisting of RIPK1, RIPK3 and MLKL. In this study, by screening of a small-compound library, we identified dozens of compounds that inhibited TNF-induced necroptosis. According to the mechanisms by which they inhibited necroptosis, these compounds were classified into different groups. We then identified Ibrutinib as an inhibitor of RIPK3 and found that Quizartinib protected against the TNF-induced systemic inflammatory response syndrome in mice by inhibiting the activation of RIPK1. Altogether, our work revealed dozens of necroptosis inhibitors, suggesting new potential approaches for treating necroptosis-related diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517925 | PMC |
| http://dx.doi.org/10.1038/s42003-023-05353-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dovitinib Ameliorates Inflammation-Related Diseases by Inhibiting Necroptosis and Ferroptosis.
ACS Chem Biol
August 2025
The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350004, China.
Abnormal and dysregulated cell death plays important roles in organ injury. Necroptosis and ferroptosis are two distinct types of regulated cell death that can trigger inflammation and are involved in organ injury. The inhibition of necroptosis and ferroptosis is proposed to be beneficial for treating multiple pathological conditions.
View Article and Find Full Text PDFFDA-approved phensuximide inhibits RIPK1-dependent immunogenic cell death.
Cell Death Dis
June 2025
Department of Biochemistry, Ajou University School of Medicine, Suwon, 16499, Republic of Korea.
Receptor-interacting serine/threonine kinase 1 (RIPK1) is a pivotal protein controlling cell death and inflammation. RIPK1 is an attractive therapeutic target, given that the inhibition of RIPK1 kinase activity has been shown to be effective in animal models of human diseases such as autoimmune and neurodegenerative diseases. Here, we screened a collection of drugs with structural similarity to necrostatin-1 (Nec-1), an inhibitor of RIPK1, to assess their abilities to regulate RIPK1-mediated immunogenic cell death.
View Article and Find Full Text PDFGW806742X can induce mouse MLKL activation by directly promoting MLKL kinase like domain dimerization.
Exp Cell Res
May 2025
School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China; Beigene, Ltd., Shanghai, 200020, China. Electronic address:
The dimerization of the MLKL kinase-like domain (KLD) is a crucial step for MLKL activation in necroptosis. In 2014, it was discovered that GW806742X can directly bind to the mouse MLKL KLD via surface plasmon resonance (SPR) (Kd = 9.3 μM), inhibiting TNF-induced membrane translocation of MLKL and necroptosis.
View Article and Find Full Text PDFDiscovery of a novel quinoline RIP1 inhibitor and its treatment of acute liver injury in mice.
Bioorg Chem
June 2025
Key Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area (Ningxia Medical University), Ministry of Education, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China. Electronic address:
Necroptosis is closely associated with the development of inflammatory diseases, including acute liver injury. However, the precise role of necroptosis-related signature proteins in acute liver injury remains incompletely understood. Previously, our group investigated Compound o1, a RIP1 inhibitor, but its antinecroptosis activity and RIP1 binding affinity were suboptimal.
View Article and Find Full Text PDFTRAF2 and RIPK1 redundantly mediate classical NFκB signaling by TNFR1 and CD95-type death receptors.
Cell Death Dis
January 2025
Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Auvera Haus Grombühlstraße 12, 97080, Würzburg, Germany.
This study suggests a modified model of TNFR1-induced complex I-mediated NFκB signaling. Evaluation of a panel of five tumor cell lines (HCT116-PIK3CAmut, SK-MEL-23, HeLa-RIPK3, HT29, D10) with TRAF2 knockout revealed in two cell lines (HT29, HeLa-RIPK3) a sensitizing effect for death receptor-induced necroptosis and in one cell line (D10) a mild sensitization for TNFR1-induced apoptosis. TRAF2 deficiency inhibited death receptor-induced classical NFκB-mediated production of IL-8 only in a subset of cell lines and only partly.
View Article and Find Full Text PDF